ESMO 2023 BioNTech Data
All patients had received anti-PD1
and anti-CTLA-4 therapy
• Patients had received a median of
3 prior therapies
BNT221 in Heavily Pretreated Melanoma Patients
Phase 1 FIH study (NCT04625205): Baseline characteristics.
Borgers J. et al. Presented at ESMO 2023. Abstract #10170.
Baseline patient characteristics
Median age (range)
Sex M/F, n (%)
ECOG 0-1, n (%)
Stage IV at entry, n (%)
Serum LDH increased, n (%)
Tumor Burden at Prescreen
median sum of TL, range (mm)
Prior lines of systemic therapy median (min/max)
Prior aPD-1 therapy, n (%)
Total (n=9)
57 (32-72)
2 (22%) 7 (78%)
9 (100%)
9 (100%)
1 (11%)
44 (16-177)
3 (2/4)
9 (100%)
6 (67%)
4 (44%)
1 (11%)
9 (100%)
2 (22%)
2 (22%)
Adjuvant
Metastatic
Both
Prior aCTLA-4 therapy, n (%)
Prior BRAF/MEK-directed therapy, n (%)
Other, n (%)
BRAF: V-Raf Murine Sarcoma Viral Oncogene Homolog B; ECOG: Eastern Cooperative Oncology Group; F: female, LDH: lactate dehydrogenase; M: male,; MEK: Mitogen-activated protein kinase kinase; TL: target lesion.
23
BIONTECHView entire presentation